The Effect of Online Hemodiafiltration on Infections: Results from the CONvective TRAnsport STudy

PLoS One. 2015 Aug 19;10(8):e0135908. doi: 10.1371/journal.pone.0135908. eCollection 2015.

Abstract

Background: Hemodialysis (HD) patients have a high risk of infections. The uremic milieu has a negative impact on several immune responses. Online hemodiafiltration (HDF) may reduce the risk of infections by ameliorating the uremic milieu through enhanced clearance of middle molecules. Since there are few data on infectious outcomes in HDF, we compared the effects of HDF with low-flux HD on the incidence and type of infections.

Patients and methods: We used data of the 714 HD patients (age 64 ±14, 62% men, 25% Diabetes Mellitus, 7% catheters) participating in the CONvective TRAnsport STudy (CONTRAST), a randomized controlled trial evaluating the effect of HDF as compared to low-flux HD. The events were adjudicated by an independent event committee. The risk of infectious events was compared with Cox regression for repeated events and Cox proportional hazard models. The distributions of types of infection were compared between the groups.

Results: Thirty one percent of the patients suffered from one or more infections leading to hospitalization during the study (median follow-up 1.96 years). The risk for infections during the entire follow-up did not differ significantly between treatment arms (HDF 198 and HD 169 infections in 800 and 798 person-years respectively, hazard ratio HDF vs. HD 1.09 (0.88-1.34), P = 0.42. No difference was found in the occurrence of the first infectious event (either fatal, non-fatal or type specific). Of all infections, respiratory infections (25% in HDF, 28% in HD) were most common, followed by skin/musculoskeletal infections (21% in HDF, 13% in HD).

Conclusions: HDF as compared to HD did not result in a reduced risk of infections, larger studies are needed to confirm our findings.

Trial registration: ClinicalTrials.gov NCT00205556.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Infections / epidemiology*
  • Female
  • Hemodiafiltration / adverse effects*
  • Hemodiafiltration / methods*
  • Hospitalization
  • Humans
  • Kidneys, Artificial
  • Male
  • Middle Aged
  • Respiratory Tract Infections / epidemiology*
  • Risk
  • Skin Diseases, Infectious / epidemiology*

Associated data

  • ClinicalTrials.gov/NCT00205556

Grants and funding

CONTRAST is financially supported by a grant from the Dutch Kidney Foundation (Nierstichting Nederland, grant C02.2019) and unrestricted grants from Fresenius Medical Care (The Netherlands) and Gambro Lundia AB (Sweden). Additional support was received from the Dr. E.E. Twiss Fund, Roche Netherlands; the International Society of Nephrology/Baxter Extramural Grant Program; the Dutch Organization for Health Research and Development (ZonMW, grant 17088.2802). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.